Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™

Younossi ZM 1 , Yu ML 2 , Yilmaz Y 3 , Alswat KA 4 , Buti M 5 , Fernandez MIC 6 Show all authors , Papatheodoridis G 7 , Hamid SS 8 , El-Kassas M 9 , Chan WK 10 , Duseja AK 11 , Gordon SC 12 , Eguchi Y 13 , Isakov VA 14 , Roberts SK 15 , Fan JG 16 , Singal AK 17 , Romero-Gómez M 18 , Ahmed A 19 , Ong J 20 , Lam BP 1 , Younossi I 21 , Nader F 21 , Racila A 21 , Stepanova M 1 , Alqahtani S 21

Affiliations 

  • 1 Center for Liver Diseases, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA
  • 2 School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan
  • 3 Liver Research Unit, Institute of Gastroenterology, Marmara University, İstanbul, Turkey
  • 4 Liver Disease Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia
  • 5 Liver Unit, Universitario Vall d'Hebron and CIBEREHD del Instituto Carlos III, Barcelona, Spain
  • 6 Institute of Gastroenterology, University of Medical Science, Havana, Cuba
  • 7 Academic Department of Gastroenterology, General Hospital of Athens "Laiko", Medical School of the National and Kapodistrian University of Athens, Athens, Greece
  • 8 Department of Medicine, Aga Khan University, Karachi, Pakistan
  • 9 Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
  • 10 Department of Gastroenterology and Hepatology, University of Malaya, Kuala Lumpur, Malaysia
  • 11 Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
  • 12 Department of Hepatology and Gastroenterology, Henry Ford Hospital System, Wayne State University School of Medicine, Detroit, Michigan, USA
  • 13 Loco Medical General Institute, Saga, Japan
  • 14 Division of Gastroenterology and Hepatology, Federal Research Center of Nutrition and Biotechnology, Moscow, Russia
  • 15 Department of Medicine, Monash University, Melbourne, Australia
  • 16 Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
  • 17 University of South Dakota and Avera Transplant Institute, Sioux Falls, South Dakota, USA
  • 18 Digestive Diseases Department, Virgen del Rocío University Hospital, Institute of Biomedicine of Seville, University of Seville, Seville, Spain
  • 19 Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California, USA
  • 20 College of Medicine, University of the Philippines, Manila, Philippines
  • 21 Center for Outcomes Research in Liver Diseases, Washington, DC, USA
J Viral Hepat, 2023 Apr;30(4):335-344.
PMID: 36601668 DOI: 10.1111/jvh.13800

Abstract

Chronic hepatitis B (CHB) infection is one of the most common causes of cirrhosis and liver cancer worldwide. Our aim was to assess clinical and patient-reported outcome (PRO) profile of CHB patients from different regions of the world using the Global Liver Registry. The CHB patients seen in real-world practices are being enrolled in the Global Liver Registry. Clinical and PRO (FACIT-F, CLDQ, WPAI) data were collected and compared to baseline data from CHB controls from clinical trials. The study included 1818 HBV subjects (48 ± 13 years, 58% male, 14% advanced fibrosis, 7% cirrhosis) from 15 countries in 6/7 Global Burden of Disease super-regions. The rates of advanced fibrosis varied (3-24%). The lowest PRO scores across multiple domains were in HBV subjects from the Middle East/North Africa (MENA), the highest - Southeast/East and South Asia. Subjects with advanced fibrosis had PRO impairment in 3 CLDQ domains, Activity of WPAI (p  0.10). The clinico-demographic portrait of CHB patients varies across regions of the world and enrollment settings. Advanced fibrosis and non-hepatic comorbidities are independently associated with PRO impairment in CHB patients.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications